Login to Your Account

Spectrum prepares NDA as late-stage pipeline pumps out promise

By Marie Powers
Staff Writer

Wednesday, April 23, 2014
Spectrum Pharmaceuticals Inc. looked toward another win in its late-stage pipeline as Captisol-enabled (propylene glycol-free) melphalan met the primary endpoints in a pivotal phase II safety and efficacy study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription